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A concentration of 88mg/ml was determined for the first 
batch of CXCL9, and 56mg/ml for the second. These 
concentrations reflect a good expression of the CXCL9 
protein. The proper conditions for CXCL9 to be knocked 
out of solution were tested. 12mg/mL was tested at first, 
this proved to be a weak concentration as no proteins 
crystallized. Even at an extremely high concentration of 
88mg/mL, only three well out of 96 wells showed some 
sort of crystals. However, these crystals could also be 
inorganic salt precipitates. Since the protein is unable to be 
knocked out of solution, it could be too stable. The protein 
could also not be folded correctly and in solution like a big 
noodle; therefore, not allowing crystallization to happen. I 
would have liked to have a crystal structure by now, but 
due to the current climate that was not able to happen. 
Currently, I am working figuring out how to mutate the 
protein to decrease stability, if the protein is too stable. 
Furthermore, A2 and B22 virial coefficients might be 
helpful in terms of the fact that they can be manipulated for 
crystallography. A virial coefficient can be manipulated to 
provide correction to the ideal gas law and are 
characteristic of the interaction potential between particles 
and depend on the temperature [6]. This coefficient may be 
useful to manipulate within the well system in order to 
achieve proper crystallization. 
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Chemokines are proteins that induce tissue 
extravasation, promote differentiation, and induce 
chemotaxis. Because of these properties, the chemokine’s 
role in antitumor immune response is of great interest to 
researchers. The CXCL9,10,11/CXCR3 axis is specific in 
that it regulates immune cell migration, differentiation, and 
activation, leading to tumor suppression. CXCL9 mainly 
mediates lymphatic infiltration to the focal sites and 
suppresses tumor growth. In this research, we expressed 
the novel CXCL9 protein within competent BL21 cells. 
Two variations of a pET22b plasmid were used, one with 
PelB (to cleave initial methionine on protein sequence) and 
one without. It was found that after induction, CXCL9 was 
expressed without the PelB leader sequence. From here we 
purified the CXCL9 protein and deduced that the overall 
expression of the protein was more than favorable. After 
isolating and concentrating the protein, a final 
concentration of 92 mg/ml was determined. With the 
purified protein, X-ray crystallographic studies will be used 
to determine the 3-D structure of the protein. This interface 
is important because it will impact the interaction with the 
receptor; therefore, altering the CXCL9/CXCR3 axis. 
Abstract
A transformation of three pET22b plasmids into 
competent Bl21(DE3) cells was performed. The three 
plasmids were wild type CXCL9, control, and CXCL9 with 
PelB following Agilent Technologies Bl21(DE3) 
competent cells protocol. An SDS-Page gel was run in 
order to determine if PelB was effective. 
An LB+ ampicillin 15 mL culture from a fresh Bl21 
colony transformed with pET22b was set in a shaker 
incubator overnight at 37*C. A subculture of 1:100 into LB 
liquid was created and placed in shaker incubator for 2 
hours at 37*C. The culture was induced with 1.5mL 1M 
IPTG for 4 hours in a shaker incubator at 37*C. The cells 
were harvested and spun down at 8krpm. The pellets were 
then re-suspended in 30 mL 1XpBS+1%TX-
100+1/5Protease tablet. The re-suspended cells were 
French Pressed twice. The cells were spun down again at 
16 krpm for 25 minutes. Each pellet was re-suspended in 
30 mL wash buffer and spun down again under the same 
conditions, this was repeated twice. The pellets were re-
suspended in 6M Guanadine HCl to release the protein into 
the supernatant. An SDS page gel was ran for samples from 
the French press to the last wash. The supernatant was 
diluted 1:100 into refolding buffer and added dropwise, 
constantly stirring overnight at 4*C. 
Once the protein of interest was isolated, it underwent 
purification procedures. The protein solution was run 
through an FPLC machine, the fractions were collected, 
and an SDS-page gel was ran to determine suitable 
fractions to pool. Next, the pooled fractions were run 
through an HPLC machine, and only the distinct peak 
containing the protein of interest was collected. The 
purified protein solution was condensed and then 
lyophilized overnight. The final purified product was re-
suspended in 500uL of ddH2O, and an SDS-Page gel was 
ran of oxidized and reduced samples of CXCL9 to ensure 
the right protein was purified. 
Crystallization protocols were followed. 12mg/mL of 
protein concentration was used, and then 88mg/mg of 
protein into pre-made wells from various distributors to 
maximize the possibility of crystallization using and NT8 
Formulatrix Drop Setter. 
Methodology
The overall goal of the research is to purify CXCL9 and then use X-ray crystallography in order 




Chemokines are small proteins, 8-15kD, which interact with G protein-coupled receptors in order to induce chemotaxis, tissue extravasation, 
and promote differentiation [1]. The CXCL9, 10, 11/CXCR3 axis is important because it regulates the differentiation of naive T cells to T 
helper 1 cells and leads to the migration of immune cells to specific tissues [5]. Due to these properties, the role of this specific axis in anti-
tumor immune response is of great interest. The CXCL9, 10, 11/CXCR3 axis activates the paracrine axis, and inhibits the autocrine axis which 
makes it a favorable target for drug development [5]. It has been shown that agents who change the paracrine CXCL9,10,11 expression, and 
neutralize CXCR3 expression on cancer cells have shown anti-tumor activity in certain models [5]. Research has shown that plasmid borne 
CXCL9 plus cisplatin changed colon and lung cancer reduction and cytotoxic lymphocyte activation [7]. Additionally, intra- tumoral CXCL9 
and interleukin 2 in renal cell carcinoma tumor model ended up reducing tumor growth and angiogenesis [3]. CXCL12, a similar small protein 
ligand, has been found to bind to heparin, and work with glycosaminoglycans to sequester the ligand to CXCR4 [2]. Identifying certain small 
molecules that bind the CXCL9 will be beneficial because the small molecules can alter the function of the ligand and alter the 
CXCL9/CXCR3 interaction and function, or will help describe how the ligand is sequestered and presented to the receptor. 
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Figure 1: SDS-Page gel of 
induced and uninduced samples 
of WT and PelB CXCL9. (A)
Induced samples 1-6, induced 
PelB samples 1-3. CXCL9 is 
expressed in the induced samples 
by a characteristic dark band (red 
outline) from the WT plasmids. 
The induced PelB 1-3 samples 
show no clear expression of the 
CXCL9 protein. (B) Induced PelB 
samples 4-6 show no clear 
expression of CXCL9. Uninduced 
samples were ran as a reference.   
Figure 2: SDS-Page of final purified CXCL9 product, batch 1. The 
final concentration of 2 purification batches was determined to be 
88mg/mL and 56mg/mL. A serial dilution was performed on the 
concentrated product, starting with a 1:50 dilution of  protein to ddH2O, 
two times. The left side of the gel shows reduced CXCL9 treated with 
DTT. The reduced CXCL9 sample is shown to have traveled farther 
down the gel, which is expected as the disulfide bonds within the 
chemokine break. The right side of the gel shows the oxidized version of 
CXCL9. The oxidized chemokine should travel less distance through the 
gel when compared to the reduced version, as seen by the spacers under 
the protein band on the right. The density within each band series 
decreases as the dilution ratio increases. 
Figure 3: Three X-Ray Crystallography Hampton HT plates 
from 0 to 19 days with 0.4uL of an 88mg/mL CXCL9 
concentration and 150uL well volume. Cells B1, C9 and F2 
were determined to have some sort of crystalline structure. (B1)
0.2M Na3 Cit, 0.1M Tris 8.5 pH, 30 %v/v PEG 400. (C9) 4M Na 
form. (F2) 0.2M K Na Tart, 0.1M Na3 Cit 5.6 pH, 2M 
(NH4)2SO4. 
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